Manoj Majmudar, MD
Pulmonary Disease · Hopkinsville, KYNPI 1659336097
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,300 of the $16,708 with a category attached, or 85.6%. It is spread thinly across 56 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.
Across 822 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$1K
- Inspire Medical Systems, Inc.$1K
- Olympus Corporation Of The Americas$976
- Sanofi$854
- plus $8K from 50 others
What the payments were for
- Consulting fees$3502%
- Travel & lodging$1,5349%
- Food & beverage$14,30086%
- Education$5243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire Upper Airway Stimulation System$800
- SINGLE USE SUCTION VALVE (Sterile)$512
- SYMBICORT$264
- FASENRA$264
- FARXIGA$226
- LUMRYZ$200
- XYWAV$150
- XYREM$150
- TEZSPIRE$141
- BREZTRI$141
- MOUNJARO$125
- BREZTRI AEROSPHERE$123
- CHARTIS CATHETER$123
- ZEPHYR DELIVERY CATHETER$123
- ZEPHYR ENDOBRONCHIAL VALVE$123
- PULMONX CHARTIS TABLET CONSOLE$123
How this compares
$16,708 in reported general payments places this provider in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 466 | $365,932 |
| EliquisApixaban | 1,083 | $348,473 |
| Dupixent PenDupilumab | 78 | $291,992 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 273 | $242,816 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $219,755 |
| Fasenra PenBenralizumab | 28 | $160,289 |
| OfevNintedanib Esylate | 12 | $155,958 |
| AustedoDeutetrabenazine | 26 | $140,839 |
| FarxigaDapagliflozin Propanediol | 262 | $138,343 |
| TrulicityDulaglutide | 187 | $127,986 |
| XareltoRivaroxaban | 328 | $116,898 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 186 | $107,225 |
| Breo ElliptaFluticasone/Vilanterol | 216 | $97,297 |
| Dupixent SyringeDupilumab | 24 | $90,097 |
| JardianceEmpagliflozin | 234 | $87,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,668 | $616,161990 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Lokelma | $2,830 | $423,718659 claims |
| PfizerEliquis, Nurtec Odt | $504 | $402,0911,113 claims |
| Boehringer IngelheimOfev, Jardiance, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,280 | $375,457456 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $215 | $219,75513 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $399 | $158,442212 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $113 | $140,83926 claims |
| Johnson & JohnsonXarelto | $340 | $116,898328 claims |
| Novo NordiskOzempic | $122 | $80,29677 claims |
| AbbVieLinzess | $59 | $73,267113 claims |
| MerckJanuvia | $56 | $62,112185 claims |
| NovartisEntresto | $69 | $47,755141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Hopkinsville
- Sanjay ChavdaHopkinsville$9K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
- Karim El-KershLouisville$180K
- Dennis DohertyLexington$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.